Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

KURA

NASDAQ

Kura Oncology (KURA)

11 USD −6.22% vs prior close Sep 23, 2026
Kura Oncology, Inc. price graph
22 sessions
14 10 24 Aug 23 Sep

The line runs 12.87 USD on 24 August through 11 USD on 23 September, on a scale from 10 to 14. Days the market did not trade hold the previous close, flat.

Market cap
1.0B USD
Revenue, year to Dec 2025
67.5M USD
EPS, diluted, year to Dec 2025
−3.18 USD
52-week range
7.39 USD – 13.59 USD
Avg volume
132.1K

as of Sep 23, 2026

Have Kura Oncology (KURA) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Kura Oncology insiders reported 18 open-market sales and 3 purchases (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 19 Nov 2026

3buys
18sells
$814Knet bought
1other filings
Have Kura Oncology (KURA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
19 Nov 2026Powl Brian T.Chief Commercial OfficerSell4483K USD
17 Nov 2026FORD KATHLEENChief Operating OfficerSell3,66827K USD
17 Nov 2026Powl Brian T.Chief Commercial OfficerSell15,254114K USD
17 Nov 2026Leoni MollieChief Medical OfficerSell22,241166K USD
16 Nov 2026WILSON TROY EDWARDPresident and CEOBuy101,119750K USD
16 Nov 2026Bair Teresa BrophyChief Legal OfficerSell8,60164K USD
16 Nov 2026DOYLE THOMAS JAMESSVP, Finance & AccountingSell4,69735K USD
16 Nov 2026FORD KATHLEENChief Operating OfficerSell7,04252K USD
16 Nov 2026Powl Brian T.Chief Commercial OfficerSell9,19668K USD
16 Nov 2026Leoni MollieChief Medical OfficerSell19,009141K USD
13 Nov 2026WILSON TROY EDWARDPresident and CEOBuy98,881754K USD
29 Sep 2026FORD KATHLEENChief Operating OfficerSell3,66839K USD
Bought3 open-market purchases300,000$2.74M
Sold18 open-market sales208,205$1.93M

Showing the 12 most recent of 21 open-market trades in this window. The figures above count all of them.

1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Kura Oncology (KURA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
24 Sep 2026Burrows FrancisChief Scientific OfficerOption exercise30,000185K USD

Which funds hold Kura Oncology (KURA)?

8 of the 45 institutional funds we track reported a Kura Oncology position for the quarter ended 30 Sep 2026 — a combined 92.9M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Kura Oncology (KURA)?
FundPositionSharesValueShares q/q
AQR Capital ManagementHeld (±25%)3,688,89239.5M USD+18.0%
Renaissance TechnologiesHeld (±25%)2,005,26521.5M USD+20.5%
Two Sigma InvestmentsAdded864,4019.3M USD+415.8%
Citadel AdvisorsAdded680,1197.3M USD+107.3%
Fisher Asset ManagementHeld (±25%)565,3006.1M USD−9.7%
Man GroupHeld (±25%)467,0745.0M USD+7.9%
Millennium ManagementTrimmed358,4023.8M USD−49.6%
Tudor Investment CorpHeld (±25%)42,940460K USD−1.3%

Have members of Congress traded Kura Oncology (KURA)?

The most recent congressional trade disclosed in Kura Oncology is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.

STOCK Act disclosures

Have members of Congress traded Kura Oncology (KURA)?
TradedMemberTypeAmountFiled after
12 Dec 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD39 days

What has been filed or recorded for Kura Oncology (KURA)?

The filings we hold for Kura Oncology, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 27 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Kura Oncology (KURA)?
And
27 Oct 2026Fails to deliverShares failed to deliver28,637 shares275K USD notional · 0.031% of shares out
08 Oct 2026Fails to deliverShares failed to deliver429 shares5K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.78 USDRevenue $23M
30 Sep 2026FinancialsTotal assets566.5M USDat period end
30 Sep 2026FinancialsTotal equity18.0M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.77 USDRevenue $21M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.83 USDRevenue $18M
31 Dec 2025Annual reportFY 2025 reportedEPS −3.18 USDRevenue $67M
31 Dec 2025FinancialsRevenue67.5M USDfiscal year
31 Dec 2025FinancialsNet income−278.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.18 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.85 USDRevenue $21M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.75 USDRevenue $15M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.66 USDRevenue $14M
31 Dec 2024Annual reportFY 2024 reportedEPS −2.02 USDRevenue $54M

What do people ask about Kura Oncology (KURA)?

From live data
What did Kura Oncology shares close at?11.00

Kura Oncology closed at 11.00 USD on 23 Sep 2026, down 6.22% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Kura Oncology’s market cap?1.0B

Kura Oncology is worth 1.0B USD by market value as of 23 Sep 2026, which is the share price times the shares on issue from its SEC filings.

What is Kura Oncology’s revenue?67.5M

Kura Oncology reported revenue of 67.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Kura Oncology insiders bought or sold shares recently?18 sales

In the 90 days to 22 Nov 2026, Kura Oncology insiders reported 18 open-market sales and 3 purchases (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Kura Oncology?8 of 45

8 of the 45 funds we track reported a Kura Oncology position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Two Sigma Investments. See Funds

Have members of Congress traded Kura Oncology?1 trade

Yes. 1 trade in Kura Oncology appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Kura Oncology last report earnings?−0.78

Kura Oncology last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.78 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings
  11. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words